Home / Market News / $LXEO

$LXEO news and market catalysts

The 6 most recent market catalysts affecting $LXEO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 3 high impact 4 bullish 1 bearish Biotechnology
Nov 17, 2026 Corporate Catalyst Bullish Impact 85
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 and Q3 2026 Financial Results
Lexeo Therapeutics reported positive interim Phase I/II results for LX2020, its gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The data showed an 80% mean reductio…
Nov 16, 2026 Corporate Catalyst Bullish Impact 85
Lexeo Therapeutics Announces Positive Interim Data from HEROIC-PKP2 Phase I/II Clinical Trial
Lexeo Therapeutics reported positive interim data from its HEROIC-PKP2 Phase I/II clinical trial for LX2020, an AAV-based gene therapy targeting PKP2-associated arrhythmogenic card…
Nov 15, 2026 Corporate Catalyst Neutral Impact 55
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update
Lexeo Therapeutics has scheduled its Q3 2026 earnings release and a business update for November 16, 2026. This is a standard corporate event for publicly traded companies, providi…
Sep 22, 2026 Corporate Catalyst Bullish Impact 65
Lexeo Therapeutics Announces Deal To Acquire Mantle Therapeutics For $8.3M Upfront, Up To $13M In Milestones, Adding Friedreich Ataxia Programs
This headline represents a corporate catalyst for Lexeo Therapeutics, indicating strategic expansion into Friedreich Ataxia programs. The relatively small upfront payment ($8.3M) s…
Aug 12, 2026 Corporate Catalyst Bearish Impact 92
Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate
Lexeo Therapeutics announced Q2 earnings per share of $(0.30), which fell short of the consensus estimate of $(0.28). More critically, this loss represents a 50% increase from the …
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
Lexeo Therapeutics Says FDA Grants RMAT Designation To LX2020 Gene Therapy For PKP2-ACM Based On Interim Phase I/II HEROIC-PKP2 Data
The RMAT (Regenerative Medicine Advanced Therapy) designation is a significant regulatory milestone, indicating the FDA's recognition of LX2020's potential to address an unmet medi…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.